Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.
about
The effect of rituximab on vaccine responses in patients with immune thrombocytopeniaVaccinations for rheumatoid arthritis.Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.Rituximab for the treatment of rheumatoid arthritis: an update.Vaccination against infection in patients with multiple sclerosis.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.Vaccines and biologics.Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases.Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients.[Immunization in children and adolescents with rheumatic and musculoskeletal diseases].Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.Epstein-Barr virus infection transforms CD25+ B cells into antibody-secreting cells in rheumatoid arthritis patients.Current perspective on rituximab in rheumatic diseases.[Pneumococcus vaccination in immunosuppressed patients: current recommendations].Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
P2860
Q33409067-9C395B8D-A67E-4A8B-8B76-18586F54DBD1Q34424563-F02F77A9-2F10-4A1F-BB7C-50D86049DBEBQ36488282-D5075D8C-75D7-4637-962A-0FCC220D49DBQ37444678-A4004304-2E39-41DB-A1F9-E62F5F4A9DF8Q37978121-B1A891D6-5084-4A37-BD32-233C1A0D03C5Q38071110-D151072B-1A19-4E1C-B706-DC45BE589547Q38097170-0FB49C53-C154-43A4-9C98-FB99287A9C97Q38213192-94665CDB-5F1E-4D3E-9495-3B68F465C5FBQ38266287-FF9B1DA8-2DCA-4BF8-971C-AE218A150B65Q38842494-1CC9460C-E0BB-4CD5-842D-CB2B85A6FBEEQ41614692-30B604BC-8F35-4079-A3B3-CB44A99877B3Q42215038-FBBEA14A-D16C-4074-ADA6-802D3ED4FD6BQ42284576-FE67A448-7DE6-473E-AB39-B5E2734AD721Q42373160-871E6872-AA1A-41C9-A26F-CEF9A620B9CBQ44820384-7515024E-5486-4810-9482-29AF8F313EF3Q45361114-E45C3C9B-59D7-4902-8D82-3EB275064C19
P2860
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Vaccination response to protei ...... tis after rituximab treatment.
@ast
Vaccination response to protei ...... tis after rituximab treatment.
@en
Vaccination response to protei ...... tis after rituximab treatment.
@nl
type
label
Vaccination response to protei ...... tis after rituximab treatment.
@ast
Vaccination response to protei ...... tis after rituximab treatment.
@en
Vaccination response to protei ...... tis after rituximab treatment.
@nl
prefLabel
Vaccination response to protei ...... tis after rituximab treatment.
@ast
Vaccination response to protei ...... tis after rituximab treatment.
@en
Vaccination response to protei ...... tis after rituximab treatment.
@nl
P2093
P2860
P356
P1476
Vaccination response to protei ...... itis after rituximab treatment
@en
P2093
Gunilla Håwi
Kiandoht Zendjanchi
Maria I Bokarewa
Maria Rehnberg
Mikael Brisslert
P2860
P2888
P356
10.1186/AR3047
P50
P577
2010-06-08T00:00:00Z